Loading company…
Versantis AG is a biotech company developing treatments for acute-on-chronic liver failure and other rare liver diseases.
Versantis AG develops pharmaceutical products for rare and life-threatening liver diseases, including acute-on-chronic liver failure, with a pipeline of five assets. Its revenue comes from partnerships, milestone payments and royalties, including with Ipsen. Founded in 2015 and based in Zurich, Switzerland, the company was acquired by Genfit in September 2022 for CHF 40 million, with contingent consideration. It is at the Series B stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in